Pain as the fifth vital sign

Pain as the fifth vital sign was a campaign to make pain a routine part of medical assessment, alongside blood pressure, heart rate, respiratory rate, and temperature. Its promise was to correct longstanding undertreatment; its consequence was a clinical system that increasingly scored pain and treated relief as a measurable goal, even though pain is subjective and the effects of the new approach were not well established. In the account of the opioid crisis, the expression marks a collision between humane attention to suffering, institutional incentives, and the commercial promotion of opioid medication.

From neglected symptom to clinical measure

By the mid-1990s, many health professionals regarded pain as undertreated, in part because outdated beliefs about addiction were thought to make clinicians reluctant to provide adequate relief. A 2000 article in The New York Times illustrated the concern through an older nursing-home resident whose severe osteoporosis and pulmonary disease were treated with Tylenol. The case represented a broader challenge to medical practice: patients’ pain could be dismissed or left insufficiently treated, and clinicians needed to take it seriously.

The fifth-vital-sign idea offered an administratively legible answer. In 1996, as OxyContin entered the market, doctors, hospitals, and accreditation bodies were adopting the idea that pain deserved the same routine attention as the other vital signs. In 1999, the Joint Commission on Accreditation of Healthcare Organizations approved mandatory standards for pain assessment and treatment. The change gave institutions a common expectation: pain should be assessed, recorded, and addressed rather than treated as a secondary concern.

The concept also took shape amid a wider transformation in health care. Patients were increasingly treated as consumers whose experiences were measured through formal surveys, including those administered by Press Ganey. Hospitals and clinicians faced pressure to earn strong patient ratings and protect reimbursements. Within that environment, pain scores did more than describe a patient’s experience: they could become a practical signal that treatment was expected. The drive to recognize neglected pain thus entered institutions already oriented toward measurement, comparison, and performance.

A clinical standard meets a commercial campaign

Purdue Pharma presented OxyContin as a safe, reliable treatment for chronic pain and promoted the claim that addiction was rare when the medicine was used as prescribed. The company’s pain specialist, David Haddox, advanced a reported addiction rate of less than 1 percent, and Purdue’s sales representatives carried the message to doctors and dentists across all fifty states. They presented prescribing the drug not only for cancer pain but also for such conditions as back injuries, wisdom-tooth surgery, bronchitis, and temporomandibular joint disorder as responsible and compassionate care.

The fifth-vital-sign movement did not itself create Purdue Pharma’s marketing strategy, but the two developments reinforced one another. The new standards made pain assessment an institutional responsibility; the company positioned itself as an authority able to help health-care providers meet that responsibility. In a 2000 budget plan, Purdue Pharma described an opportunity to be seen as a leader in helping hospitals comply with the Joint Commission’s requirements by supplying assessment and management materials. The company planned OxyContin-branded pens and binders, as well as wall charts and clipboards bearing the fifth-vital-sign message. Clinical language and branded promotion could therefore occupy the same hospital space.

At the bedside, the measure also met pressures unrelated to a patient’s underlying condition. Emergency departments were busy, and doctors faced interruptions, demanding caseloads, and the prospect of poor patient reviews. One physician described how easy it could be to give a patient an intravenous opioid and postpone a more difficult decision. Physicians had also been taught that addiction was unlikely when opioids were used for legitimate pain. A routine pain score, combined with expectations of prompt relief and the assurance of low addiction risk, could support prescribing practices whose consequences were not fully understood.

What a number could—and could not—show

The appeal of a pain scale was partly its apparent simplicity. A number could be entered into a chart, compared across visits, and used to demonstrate that an institution had asked about pain. But the underlying experience is invisible to an observer, and no shared definition of adequate pain relief resolved how a patient’s report should guide treatment. A standardized scale made the process easier to administer without making the experience itself objectively measurable.

The limits become clear in the examples discussed in the book: transition labor and a stubbed toe could both receive a score of ten, depending on the individual’s tolerance. The same number could therefore represent very different conditions and needs. A scale could register what a person reported, but it could not by itself determine the appropriate treatment, distinguish pain that would respond to an opioid from pain that would not, or establish whether a prescription improved a patient’s life.

Clinicians later questioned whether greater reliance on pain scales correlated with better patient outcomes. The account reports that it did not, while the practice was associated with increased opioid prescribing and abuse. Physicians who had been told that short courses of opioid medication would not lead to addiction described having underestimated the risk. The difficulty was not simply that pain mattered too much or too little; it was that a measurement designed to make suffering visible could be mistaken for a treatment instruction, while the relevant risks and outcomes remained harder to measure.

Reassessment and unresolved tensions

The policy response came slowly. In 2016, the Centers for Disease Control and Prevention issued voluntary prescribing guidelines for chronic pain that strongly recommended limiting opioid use. The book emphasizes that these recommendations echoed warnings Barbara Van Rooyan had urged the Food and Drug Administration to adopt roughly a decade earlier. In the same period, the American Medical Association was urged to remove pain as the fifth vital sign from its standards of care; the institution had taken two decades to endorse that change.

Reconsideration did not mean that pain had become unimportant or that every opioid prescription was unjustified. More than half of patients taking OxyContin were still on dosages higher than the CDC suggested, while patients whose legitimate pain was controlled by the medication feared that the policy pendulum had swung too far in the opposite direction. The account also notes that painkillers enabled one journalist with severe spinal curvature, slipped disks, and arthritis pain to continue working and pursue ordinary activities, while avoiding surgery described as risky and potentially debilitating. Such cases complicate any simple division between appropriate treatment and excessive prescribing.

The expression therefore names both a corrective and a warning. It arose from a legitimate demand that clinicians acknowledge suffering, but its institutional form encouraged pain to be scored as if a number could settle what relief required. Once those scores became part of standards and patient-experience systems, they interacted with clinical habits and Purdue Pharma’s promotion of opioid medication. The later effort to revise prescribing guidance exposed what the slogan could not answer on its own: how to treat pain effectively, how to assess function as well as reported intensity, and how to protect patients from undertreatment without allowing a convenient metric to stand in for judgment.